drugset

drugset / Trial / NCT05467943

Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma

NCT05467943 ↗

Phase 2 Completed 42 enrolled Hutchmed

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Treating Relapsed/Refractory Follicular Lymphoma with Tazemetostat

Timeline

Start: 2022-07-29
Primary completion: 2024-11-30
Completion: 2024-11-30

Publications

Cao J, Chen G, Qiu L, Zhang L, Jiang M, Cheng Y, Zhang Q, Liu L, Li P, Shuang Y, Wang H, Xue H, Wu H, Zheng M, Zhou K, Li Z, Jing H, Yang W, Zhu Z, Li W, Wangwu J, Huang H, Jia Q, Chen D, Fan S, Shi MM, Su W. Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study. EClinicalMedicine. 2025 Aug 18;87:103399. doi: 10.1016/j.eclinm.2025.103399. eCollection 2025 Sep.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tazemetostat	Small molecule	800 mg	Oral

Indications